FDA to expedite review of Lilly's gastric cancer drug

10/25/2013 | Pharmaceutical Business Review Online

The FDA granted priority-review designation to Eli Lilly & Co.'s biologics license application for ramucirumab, or IMC-1121B, for treatment of patients with advanced gastric cancer whose disease progressed after initial chemotherapy. The drug is also under regulatory review in Europe.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI